Optimising the supported modes of atom or ion dispersal onto substrates, to synchronously integrate high reactivity and robust stability in catalytic conversion, is an important yet challenging area of research. Here, theoretical calculations first show that three-coordinated copper (Cu) sites have higher activity than four-, two- and one-coordinated sites. A site-selective etching method is then introduced to prepare a stacked-nanosheet metal–organic framework (MOF, CASFZU-1)-based catalyst with precisely controlled coordination number sites on its surface. The turnover frequency value of CASFZU-1 with three-coordinated Cu sites, for cycloaddition reaction of CO
2
with epoxides, greatly exceed those of other catalysts reported to date. Five successive catalytic cycles reveal the superior stability of CASFZU-1 in the stacked-nanosheet structure. This study could form a basis for the rational design and construction of highly efficient and robust catalysts in the field of single-atom or ion catalysis.
Luminescent metal–organic
frameworks (LMOFs) demonstrate
strong potential for a broad range of applications due to their tunable
compositions and structures. However, the methodical control of the
LMOF emission properties remains a great challenge. Herein, we show
that linker engineering is a powerful method for systematically tuning
the emission behavior of UiO-68 type metal–organic frameworks
(MOFs) to achieve full-color emission, using 2,1,3-benzothiadiazole
and its derivative-based dicarboxylic acids as luminescent linkers.
To address the fluorescence self-quenching issue caused by densely
packed linkers in some of the resultant UiO-68 type MOF structures,
we apply a mixed-linker strategy by introducing nonfluorescent linkers
to diminish the self-quenching effect. Steady-state and time-resolved
photoluminescence (PL) experiments reveal that aggregation-caused
quenching can indeed be effectively reduced as a result of decreasing
the concentration of emissive linkers, thereby leading to significantly
enhanced quantum yield and increased lifetime.
Owing to undesired Zn corrosion and the formation of Zn dendrites in aqueous electrolytes, most of the examples of aqueous Zn batteries with reported excellent performance are achieved with low Zn‐utilization (<0.6 %) in the anode and low mass‐loading (<3 mg cm−2) in the cathode. Herein, we propose a new organic electrolyte for Zn batteries, which contains a zinc trifluoromethanesulfonate (Zn‐TFMS) salt and a mixed solvent consisting of propylene carbonate (PC) and triethyl phosphate (TEP). We demonstrate that this electrolyte with an optimized PC/TEP ratio not only exhibits high ionic conductivity and a wide stable potential window, but also facilitates dendrite‐free Zn plating/stripping. In particular, the TEP solvent makes the electrolyte nonflammable. Finally, a 2 V Zn//polytriphenylamine composite (PTPAn) battery is fabricated with the optimized electrolyte; it shows a high rate and a long lifetime (2400 cycles) even with a high mass‐loading (16 mg cm−2) of PTPAn in the cathode and with a high Zn‐utilization (3.5 %).
While limited choice of emissive organic linkers with systematic emission tunability presents ag reat challenge to investigate energy transfer (ET) over the whole visible light range with designable directions,l uminescent metal-organic frameworks (LMOFs) may serve as an ideal platform for such study due to their tunable structure and composition. Herein, five Zr 6 cluster-based LMOFs,HIAM-400X (X = 0, 1, 2, 3, 4) are prepared using 2,1,3-benzothiadiazole and its derivativebased tetratopic carboxylic acids as organic linkers.T he accessible unsaturated metal sites confer HIAM-400X as apristine scaffold for linker installation. Six full-color emissive 2,1,3-benzothiadiazole and its derivative-based dicarboxylic acids (L) were successfully installed into HIAM-400X matrix to form HIAM-400X-L, in whichthe ET can be facilely tuned by controlling its direction, either from the inserted linkers to pristine MOFs or from the pristine MOFs to inserted linkers, and over the whole range of visible light. The combination of the pristine MOFs and the second linkers via linker installation creates ap owerfult wo-dimensional space in tuning the emission via ET in LMOFs.
Background
Age-related macular degeneration (AMD) is a leading cause of severe visual deficits and blindness. Meanwhile, there is convincing evidence implicating oxidative stress, inflammation, and neovascularization in the onset and progression of AMD. Several studies have identified berberine hydrochloride and chrysophanol as potential treatments for ocular diseases based on their antioxidative, antiangiogenic, and anti-inflammatory effects. Unfortunately, their poor stability and bioavailability have limited their application. In order to overcome these disadvantages, we prepared a compound liposome system that can entrap these drugs simultaneously using the third polyamidoamine dendrimer (PAMAM G3.0) as a carrier.
Results
PAMAM G3.0-coated compound liposomes exhibited appreciable cellular permeability in human corneal epithelial cells and enhanced bio-adhesion on rabbit corneal epithelium. Moreover, coated liposomes greatly improved BBH bioavailability. Further, coated liposomes exhibited obviously protective effects in human retinal pigment epithelial cells and rat retinas after photooxidative retinal injury. Finally, administration of P-CBLs showed no sign of side effects on ocular surface structure in rabbits model.
Conclusions
The PAMAM G3.0-liposome system thus displayed a potential use for treating various ocular diseases.
Electronic supplementary material
The online version of this article (10.1186/s12951-019-0498-7) contains supplementary material, which is available to authorized users.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.